Stay updated on Exenatide Once Weekly in Adolescent Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the Exenatide Once Weekly in Adolescent Type 2 Diabetes Clinical Trial page.

Latest updates to the Exenatide Once Weekly in Adolescent Type 2 Diabetes Clinical Trial page
- Check2 days agoChange DetectedThe page now shows Revision: v3.3.4 instead of v3.3.3; no study details or content were changed.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a consolidated Locations section with state listings (CA, CT, IA, KS, KY, MA, MS, NY, NC, OH, OK, SD, TN, TX) and removed the separate per-state Location headings, updating the study's location information.SummaryDifference1%

- Check53 days agoChange DetectedAdded a PubMed auto-fill note indicating publications may not be about the study and updated the page revision to v3.3.2. Removed the older PubMed sourcing text and the previous revision tag v3.2.0.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoved the disclaimer about a lapse in government funding and NIH Clinical Center operating status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check82 days agoChange DetectedNo changes to the core study details or eligibility criteria were detected; the differences seem to be minor formatting or layout adjustments that do not alter the content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check103 days agoChange Detected- Added a government funding lapse notice with status guidance and links; updated version to v3.2.0. - Removed the old version tag v3.1.0.SummaryDifference2%

Stay in the know with updates to Exenatide Once Weekly in Adolescent Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Exenatide Once Weekly in Adolescent Type 2 Diabetes Clinical Trial page.